Zacks Upgrades HeartWare International to Outperform (HTWR)
HeartWare International (NASDAQ:HTWR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Friday. The firm currently has a $105.70 price target on the stock. Zacks‘s target price suggests a potential upside of 28.34% from the company’s current price.
Shares of HeartWare International (NASDAQ:HTWR) opened at 82.36 on Friday. HeartWare International has a 1-year low of $69.31 and a 1-year high of $105.84. The stock’s 50-day moving average is $87.99 and its 200-day moving average is $92.05. The company’s market cap is $1.399 billion.
HeartWare International (NASDAQ:HTWR) last announced its earnings results on Thursday, July 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. On average, analysts predict that HeartWare International will post $-2.90 earnings per share for the current fiscal year.
Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for HeartWare International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.